Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-250

Saw this after I submitted my second post tonight... (and I see @James5656 has also posted a reply)

Thank you for taking the time to reply.

I've had a look at both journal articles you referred to, and note the first article you referenced used the second article as its reference for the comment you copy/pasted:
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Journal of Clinical Oncology (ascopubs.org)
Here's the full paragraph for full context:

It is worth noting that article was from 2015, whereas this article is from 2017 and specifically in relation to psuedoprogression:
Imaging Manifestations of Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene Laherparepvec: Initial Experience - PMC (nih.gov)
It is more recent but from a smaller sample and in combination with Yervoy (Ipilimumab).

I guess the main take away is that pseudoprogression is not an unlikely possibility (more than half experienced >= 25% increase before achieving a response) for patients treated with oncolytic virus therapies and we really need to wait for further updates before it can be conclusively determined if those PDs, iUPDs and SDs involve pseudoprogression or not.